Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 29, 2010American Journal of HematologyOpen Access

Biosimilar epoetins and other “follow‐on” biologics: Update on the European experiences

View Full Paper
Ask AI
Bookmark
Share

Authors

WJWolfgang JelkmannUniversity of Lübeck

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Wolfgang Jelkmann (2010) studied this question.

synapsesocial.com/papers/6a830ad9c4b5dbf8331f2945https://doi.org/10.1002/ajh.21805
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Recombinant EPO production points the nephrologist should know2007 · 59 citations
  2. 2Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS)2003 · 469 citations
  3. 3Current Methods for Detecting Antibodies against Erythropoietin and Other Recombinant Proteins2005 · 48 citations
  4. 4Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant Erythropoietin2002 · 1,248 citations
  5. 5Comparative Erythropoietin Receptor Binding Kinetics of C.E.R.A. and Epoetin-β Determined by Surface Plasmon Resonance and Competition Binding Assay2007 · 85 citations